Soft tissue sarcomas: From a morphological to a molecular biological approach

Area of Science:

• Oncology
• Molecular Genetics
• Soft Tissue Pathology

Background:

• Soft tissue sarcomas are a heterogeneous group of tumors.
• Traditional classification relies on morphology, but molecular data offers refined insights.
• Recent advances in molecular genetics have revolutionized tumor classification.

Purpose of the Study:

• To review recent molecular genetic findings in soft tissue sarcomas.
• To highlight newly identified tumor entities and their genetic alterations.
• To discuss the implications for diagnosis, classification, and therapeutic strategies.

Main Methods:

• Analysis of tumor-specific genomic alterations using molecular genetic techniques.
• Identification of novel gene fusions and amplifications.
• Correlation of molecular findings with tumor morphology, prognosis, and therapeutic targets.

Main Results:

• Reclassification of tumor entities, including angiofibroma of soft tissue (AHRR-NCOA2).
• Identification of novel fusion genes (CIC-DUX4, BCOR-CCNB3) in small round cell sarcomas.
• SMARCB1/INI1 deficient tumors expected to be reclassified based on genotype.
• MDM2 gene amplification extends dedifferentiated liposarcoma (DDLS) entity.
• Akt-mTOR pathway activation correlates with poor prognosis in spindle cell sarcomas.
• FOXM1 expression linked to aggressive behavior and chemosensitivity in synovial sarcoma.
• High expression of PRAME and NY-ESO-1 in myxoid/round cell liposarcoma and synovial sarcoma.

Conclusions:

• Molecular genetic techniques are crucial for accurate soft tissue sarcoma classification.
• Novel genetic alterations define new tumor entities and subtypes.
• Understanding these alterations opens avenues for targeted therapies and improved patient outcomes.